Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus

• Main Authors: O K Vikulova, Z T Zuraeva, O V Michaleva, L V Nikankina, M Sh Shamkhalova, M V Shestakova, I I Dedov
• Format: Article
• Language: Russian
• Published: "Consilium Medicum" Publishing house 2018-06-01
• Series: Терапевтический архив
• Subjects: type 1 diabetes mellitus; diabetic kidney disease; nephroprotective therapy; incretins; glucagon-like peptide type 1 receptor agonists
• Online Access: https://ter-arkhiv.ru/0040-3660/article/viewFile/32775/pdf

The purpose of our study is to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1R agonists) on early markers of kidney damage in patients with type 1 diabetes mellitus (DM). Materials and methods. The study included 27 patients with type 1 diabetes with normo- (n=16) and microalbuminuria (n=11) on intensive insulin injection regimen with insulin analogs. Patients were divided into two groups: 15 patients continued insulin therapy throughout the follow-up period, 12 patients were given 1.2 mg GLP-1R agonist (Liraglutide) once a day in addition to the insulin therapy for 6 months. HbA1c, lipid profile, classic markers of kidney damage (albuminuria, creatinine, glomerular filtration rate); plazma (neutrophilic gelatinase-associated lipoxalin - NGAL, molecule renal damage of type 1 - KIM-1, cystatin C, osteopontin) and urinary kidney biomarkers (nephrin, podocyne, uromodulin, NGAL, KIM-1, collagen type IV, cystatin C) were evaluated prior and in dynamics at 6 months. Kidney biomarkers levels were assessed by the enzyme-linked immunosorbent assay (ELISA). Results. We observed a significant decrease in the urinary excretion of type IV collagen, cystatin C, increased uromodulin excretion and decrease in the plasma levels of osteopontin, NGAL and cystatin C in the group of combined insulin and GLP-1R agonist therapy. Conclusions. Changes in the level of sensitive kidney biomarkers indicate a possible renoprotective effect of GLP-1R agonist therapy in patients with type 1 diabetes at an early stages of kidney damage.